Impact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C plus V): a pooled analysis

被引：0
|
作者：
Lewis, K. [1 ]
Larkin, J. [2 ]
Ribas, A. [3 ]
Flaherty, K. T. [4 ]
McArthur, G. A. [5 ]
Ascierto, P. A. [6 ]
Dreno, B. [7 ]
McKenna, E. [8 ]
Zhu, Q. [9 ]
Mun, Y. [8 ]
Hauschild, A. [10 ]
机构：
[1] Univ Colorado, Comprehens Canc Ctr, Med, Aurora, CO USA
[2] Royal Marsden Hosp NHS Fdn Trust, Oncol, London, England
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[4] Massachusetts Gen Hosp, Med, Boston, MA 02114 USA
[5] Peter MacCallum Canc Ctr, Dept Med Oncol, East Melbourne, Australia
[6] Ist Nazl Tumori Fdn Pascale, Canc Immunotherapy & Innovat Therapy Unit, Melanoma, Naples, Italy
[7] Nantes Univ, Dermatol, Nantes, France
[8] Genentech Inc, Prod Dev, San Francisco, CA 94080 USA
[9] Genentech Inc, Oncol, San Francisco, CA 94080 USA
[10] Univ Hosp Schleswig Holstein, Dermatol, Kiel, Germany
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1241P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data
    Hopkins, Ashley M.
    Van Dyk, Madele
    Rowland, Andrew
    Sorich, Michael J.
    PIGMENT CELL & MELANOMA RESEARCH, 2019, 32 (04) : 576 - 583
  • [2] Early on-therapy arthralgia predicts improved response and survival in advanced melanoma patients treated with vemurafenib and vemurafenib plus cobimetinib: A pooled analysis of clinical trial data
    Hopkins, Ashley M.
    Dyk, Madele V.
    Rowland, Andrew
    Sorich, Michael J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 187 - 187
  • [3] Prognostic subgroups and impact of treatment for post-progression overall survival (ppOS) in patients (pts) with BRAFV600-mutated metastatic melanoma treated with dacarbazine (DTIC) or vemurafenib (VEM) ± cobimetinib (COBI): A pooled analysis
    Ascierto, P. A.
    Ribas, A.
    Larkin, J.
    McArthur, G. A.
    Lewis, K. D.
    Hauschild, A.
    Flaherty, K. T.
    McKenna, E.
    Zhu, Q.
    Mun, Y.
    Dreno, B.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Atezolizumab (A) plus cobimetinib (C) plus vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.
    Sullivan, Ryan J.
    Gonzalez, Rene
    Lewis, Karl D.
    Hamid, Omid
    Infante, Jeffrey R.
    Patel, Manish R.
    Hodi, F. Stephen
    Wallin, Jeffrey
    Pitcher, Bethany
    Cha, Edward
    Roberts, Louise
    Ballinger, Marcus
    Hwu, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib±cobimetinib: a pooled analysis of four clinical trials
    Ascierto, Paolo A.
    Ribas, Antoni
    Larkin, James
    McArthur, Grant A.
    Lewis, Karl D.
    Hauschild, Axel
    Flaherty, Keith T.
    McKenna, Edward
    Zhu, Qian
    Mun, Yong
    Dreno, Brigitte
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [6] Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials
    Paolo A. Ascierto
    Antoni Ribas
    James Larkin
    Grant A. McArthur
    Karl D. Lewis
    Axel Hauschild
    Keith T. Flaherty
    Edward McKenna
    Qian Zhu
    Yong Mun
    Brigitte Dréno
    Journal of Translational Medicine, 18
  • [7] Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma
    Cai, Chao
    Yunusa, Ismaeel
    Tarhini, Ahmad
    JAMA NETWORK OPEN, 2021, 4 (11)
  • [8] Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C).
    Dreno, Brigitte
    Bartley, Karen
    Ascierto, Paolo Antonio
    Atkinson, Victoria
    Liszkay, Gabriella
    Maio, Michele
    Mandala, Mario
    Demidov, Lev V.
    Stroyakovskiy, Daniil
    Thomas, Luc
    De La Cruz-Merino, Luis
    Dutriaux, Caroline
    Garbe, Claus
    Chang, Ilsung
    Hack, Stephen Paul
    Larkin, James M. G.
    McArthur, Grant A.
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] COST-EFFECTIVENESS OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB IN THE TREATMENT OF BRAF V600 MUTATION-POSITIVE METASTATIC MELANOMA
    Cai, C.
    Yunusa, I
    Tarhini, A.
    VALUE IN HEALTH, 2022, 25 (07) : S300 - S300
  • [10] Association of depth of response with survival outcomes in prognostic groups of patients treated with cobimetinib (C) ± vemurafenib (V): A pooled analysis of the BRIM-2,-3,-7, and coBRIM studies
    Lewis, K. D.
    Larkin, J.
    Ribas, A.
    Flaherty, K. T.
    McArthur, G. A.
    Ascierto, P. A.
    Dreno, B.
    McKenna, E.
    Zhu, Q.
    Mun, Y.
    Hauschild, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 47 - 48
12345